Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience

Emicizumab is a humanized recombinant bispecific antibody, bridging together activated factor IX (FIXa) and factor X (FX), thus mimicking the activity of FVIII in vivo. Emicizumab is designed for long-term prophylaxis in patients with severe hemophilia A with and without inhibitors. This approach pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Castaman, Giancarlo, Linari, Silvia, Pieri, Lisa, Carulli, Christian, Prosperi, Paolo, Tonelli, Paolo, Demartis, Francesco, Fjerza, Rajmonda, Attanasio, Monica, Coppo, Mirella, Salvianti, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055920/
https://www.ncbi.nlm.nih.gov/pubmed/36983317
http://dx.doi.org/10.3390/jcm12062317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055920/
https://www.ncbi.nlm.nih.gov/pubmed/36983317
http://dx.doi.org/10.3390/jcm12062317

Ejemplares similares